Recombinant Human ARID3A 293 Cell Lysate
Cat.No. : | ARID3A-8727HCL |
- Specification
- Gene Information
- Related Products
Description : | Antigen standard for AT rich interactive domain 3A (BRIGHT-like) (ARID3A) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection. |
Source : | HEK 293 cells |
Species : | Human |
Components : | This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol). |
Size : | 0.1 mg |
Storage Instruction : | Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment. |
Applications : | ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane. |
Gene Name : | ARID3A AT rich interactive domain 3A (BRIGHT-like) [ Homo sapiens ] |
Official Symbol : | ARID3A |
Synonyms : | ARID3A; AT rich interactive domain 3A (BRIGHT-like); AT rich interactive domain 3A (BRIGHT like) , dead ringer like 1 (Drosophila) , DRIL1; AT-rich interactive domain-containing protein 3A; BRIGHT; dead ringer-like 1; E2F-binding protein 1; ARID domain-containing 3A; dead ringer-like protein 1; ARID domain-containing protein 3A; B-cell regulator of IgH transcription; AT rich interactive domain 3A (BRIGHT- like) protein; DRIL1; DRIL3; E2FBP1; |
Gene ID : | 1820 |
mRNA Refseq : | NM_005224 |
Protein Refseq : | NP_005215 |
MIM : | 603265 |
UniProt ID : | Q99856 |
Chromosome Location : | 19p13.3 |
Pathway : | Direct p53 effectors, organism-specific biosystem; |
Function : | DNA binding; protein homodimerization activity; sequence-specific DNA binding transcription factor activity; |
Products Types
◆ Recombinant Protein | ||
ARID3A-706M | Recombinant Mouse ARID3A Protein, His (Fc)-Avi-tagged | +Inquiry |
Arid3a-1698M | Recombinant Mouse Arid3a Protein, Myc/DDK-tagged | +Inquiry |
ARID3A-1911M | Recombinant Mouse ARID3A Protein | +Inquiry |
ARID3A-794H | Recombinant Human ARID3A protein, GST-tagged | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (11)
Ask a questionMutations in the ARID3A gene can lead to the production of abnormal ARID3A proteins that may disrupt its normal function. Additionally, genetic alterations affecting the regulation of ARID3A expression can also affect its activity.
Yes, ARID3A can interact with other proteins to form complexes that regulate gene expression. Some proteins known to interact with ARID3A include other transcription factors, chromatin remodeling proteins, and co-activators or co-repressors. These interactions help determine the specific genes that ARID3A regulates and the functional outcomes.
Currently, there are no clinical trials specifically targeting the ARID3A protein. However, its role in cancer and other diseases makes it an interesting target for potential therapies in the future.
While specific diseases directly caused by ARID3A mutations are less well-studied compared to its involvement in cancer, alterations in ARID3A expression have been linked to certain autoimmune diseases, such as systemic lupus erythematosus (SLE). These associations suggest a potential role for ARID3A in autoimmune disorders, although more research is needed to fully understand the underlying mechanisms.
While there are currently no ARID3A-specific therapies available, its involvement in cancer and other diseases makes it a potential therapeutic target. Targeting ARID3A could potentially modulate the expression of its downstream target genes and impact the disease processes associated with its dysregulation. However, more research is needed to develop specific strategies and evaluate the therapeutic potential of ARID3A targeting.
ARID3A can bind to specific DNA sequences known as enhancers and promoters, regulating the expression of various target genes. Some known targets of ARID3A include genes involved in cell cycle regulation, apoptosis, immune response, and cellular differentiation. The specific target genes can vary depending on the cell type and context.
ARID3A expression has been investigated as a potential diagnostic marker in certain cancers. For example, increased expression of ARID3A has been associated with poor prognosis in some breast cancers and has been proposed as a biomarker for predicting patient outcomes. However, more research is needed to validate ARID3A as a reliable diagnostic marker across different cancer types and diseases.
Apart from cancer, dysregulation of ARID3A has been implicated in other diseases and disorders. For example, ARID3A has been linked to autoimmune diseases like systemic lupus erythematosus (SLE), where it is involved in aberrant immune responses. Additionally, alterations in ARID3A expression or function have been observed in neurodevelopmental disorders, such as autism spectrum disorder (ASD) and intellectual disability. More research is needed to fully understand the role of ARID3A in these diseases and how its dysfunction contributes to their pathogenesis.
Yes, ARID3A is involved in embryonic development and plays a role in cell fate determination and differentiation. It has been implicated in the development of the immune system, hematopoiesis, and neural development, among other processes. Knockout or downregulation of ARID3A in animal models has shown developmental abnormalities in these systems.
Yes, genetic mutations in ARID3A have been identified in certain cancers and developmental disorders. These mutations can lead to altered expression or function of ARID3A and contribute to disease development. However, the frequency and significance of ARID3A mutations in these conditions are still fairly understudied, and more research is needed to fully understand their implications.
Alterations in ARID3A expression or activity have been observed in certain diseases, including cancer. As such, it is possible that measuring ARID3A levels or activity could serve as a diagnostic or prognostic marker in specific contexts. However, further research is needed to determine the utility of ARID3A as a biomarker.
Customer Reviews (8)
Write a reviewTheir technical expertise and experience in the field allow them to provide invaluable guidance and assistance.
Their team of experts possesses an in-depth understanding of the protein and its applications, which proves instrumental in troubleshooting and optimizing experimental protocols.
the manufacturer's dedication to innovation and continuous improvement stands out.
They continuously stay up-to-date with the latest scientific advancements and customer feedback, allowing them to refine the ARID3A protein based on emerging trends.
They provide comprehensive assistance, ensuring that any queries or concerns I have regarding the ARID3A protein are promptly addressed.
They can offer insights on experimental design, optimal usage protocols, and troubleshoot any challenges that may arise during the course of the trial.
In addition to these experimental benefits, the manufacturer of ARID3A protein plays a vital role in supporting researchers.
Its potency and specificity make it a valuable tool for studying specific biological pathways or mechanisms.
Ask a Question for All ARID3A Products
Required fields are marked with *
My Review for All ARID3A Products
Required fields are marked with *
Inquiry Basket